ArticleBMC infectious diseases2015
Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection.
Article in BMC infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 4 syntheses or guidelines pooled it, 148 citations in OpenAlex.
- Hyperimmune yolk extract with Immunoglobulin Y basic active principle as a possible adjuvant treatment in patients who need/benefit from neurorehabilitation, withJournal of medicine and life · 2022Pooled it
- Fecal Microbiota Transplantation (FMT) with Colonoscopy Is Superior to Enema and Nasogastric Tube While Comparable to Capsule for the Treatment of Recurrent Clostridioides difficile Infection: A Systematic Review and Meta-Analysis.Digestive diseases and sciences · 2021Pooled it
- Clinical remission of ulcerative colitis after different modes of faecal microbiota transplantation: a meta-analysis.International journal of colorectal disease · 2020Pooled it
- A Systematic Review of the Efficacy and Safety of Fecal Microbiota Transplant forCanadian journal of gastroenterology & hepatology · 2018Pooled it
- Capsulized Fecal Microbiota Transplantation Induces Remission in Patients with Ulcerative Colitis by Gut Microbial Colonization and Metabolite Regulation.Microbiology spectrum · 2023Trial
- A narrative review on fecal microbiota transplantation routes in ulcerative colitis: identifying the optimal approach across key parameters.Annals of medicine and surgery (2012) · 2025Review
- Evaluation of the effects of different formulations of protectants on the preservation of the microbiota in fecal microbiota transplantation.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Effects and Microbiota Changes Following Oral Lyophilized Fecal Microbiota Transplantation Capsules in Canine with Chronic Enteropathy After Parvovirus Infection: Case Report.Veterinary sciences · 2025Article
- Validation methods for encapsulated faecal microbiota transplantation: a scoping review.Therapeutic advances in gastroenterology · 2025Review
- Freeze-dried fecal microorganisms as an effective biomaterial for the treatment of calves suffering from diarrhea.Scientific reports · 2024Article
- Polysaccharide-fecal microbiota-based colon-targeted self-nanoemulsifying drug delivery system of curcumin for treating polycystic ovarian syndrome.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Validation of Lyophilized Human Fecal Microbiota for the Treatment ofMicroorganisms · 2024Article
- Fecal Microbiota Transplantation as Emerging Treatment in European Countries 2.0.Advances in experimental medicine and biology · 2024Review
- Protective effects of fecal microbiota transplantation against ischemic stroke and other neurological disorders: an update.Frontiers in immunology · 2024Review
- Microbiome dysbiosis: a modifiable state and target to prevent Staphylococcus aureus infections and other diseases in neonates.Journal of perinatology : official journal of the California Perinatal Association · 2024Review
- Is there a role for microbiome-based approach in common variable immunodeficiency?Clinical and experimental medicine · 2023Review
- Review
- Commercially Available Enteric Empty Hard Capsules, Production Technology and Application.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Review
- The Age of Next-Generation Therapeutic-Microbe Discovery: Exploiting Microbe-Microbe and Host-Microbe Interactions for Disease Prevention.Infection and immunity · 2022Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClostridium difficile infection (CDI), a complication of antibiotic-induced injury to the gut microbiome, is a prevalent and dangerous cause of infectious diarrhea. Antimicrobial therapy for CDI is typically effective for acute symptoms, but up to one third of patients later experience recurrent CDI. Fecal-derived microbiota transplantation (FMT) can ameliorate the underlying dysbiosis and is highly effective for recurrent CDI. Traditional methods of FMT are limited by patient discomfort, risk and inefficient procedures. Many individuals with recurrent CDI have extensive comorbidities and advanced age. Widespread use of FMT requires strategies that are non-invasive, scalable and applicable across healthcare settings.
methodsA method to facilitate microbiota transfer was developed. Fecal samples were collected and screened for potential pathogens. Bacteria were purified, concentrated, cryopreserved and formulated into multi-layered capsules. Capsules were administered to patients with recurrent CDI, who were then monitored for 90 days.
resultsThirteen women and six men with recurrent CDI were provided with microbiota transfer with orally administered capsules. The procedure was well tolerated. Thirteen individuals responded to a single course. Four patients were cured after a second course. There were 2 failures. The cumulative clinical cure rate of 89% is similar to the rates achieved with reported fecal-derived transplantation procedures.
conclusionsRecurrent CDI represents a profound dysbiosis and a debilitating chronic disease. Stable cure can be achieved by restoring the gut microbiome with an effective, well-tolerated oral capsule treatment. This strategy of microbiota transfer can be widely applied and is particularly appropriate for frail patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.